AtriCure, Inc.
AtriCure develops and sells devices for surgical ablation, exclusion of the left atrial appendage, and temporary pain relief. Products include Isolator Synergy Clamps, multifunctional pens, linear ablation devices, cryoablation systems, EPi-Sense Systems, cryoSPHERE probe, AtriClip System, LARIAT System, Lumitip dissectors, Glidepath guides, Subtle Cannulas, and reusable cardiac instruments.
Overview
Sector
Medical Instruments & Supplies
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (3.38) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (2.32%) is significantly lower than the sector mean (8.23%).
- EV/EBITDA (100.00) is significantly higher than the sector mean (47.53).
- EV/EBIT (100.00) is significantly higher than the sector mean.
- The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | 2.3% |
| Net Debt/EBITDA | 3.4 |